Significant decreases in the chemotherapy-induced expressions of numerous SLFN12 signature cancer genes were observed following SLFN12 overexpression, highlighting the importance of understanding the comprehensive makeup of the SLFN12 signature cancer genes to more accurately develop a personalized treatment plan for TNBC patients. The gene discussed is SLFN12; the disease is cancer.